Stockreport

Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates [Yahoo! Finance]

Trevi Therapeutics, Inc.  (TRVI) 
PDF clinical development to show benefit in patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and RCC Completed enrollment in the Phase 2b CORAL trial in [Read more]